Memorial Sloan Kettering Cancer Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Memorial Sloan Kettering Cancer Center brings 12 presentations to ASH 2026 in New Orleans. Its program spans blood cancers from lymphoma and CLL to myeloma and myelofibrosis, with recurring attention to bispecific antibodies and CAR T. It also covers microbiome-directed trials in blood cancers, including diet, prebiotic and live bacterial strategies.
| Organization | ASH 2026 Attendance |
|---|---|
Memorial Sloan Kettering Cancer Center New York, NY | |
NCI-designated comprehensive cancer center in New York City combining cancer care, research and education. | Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Symposium Fri Dec 11 3:00pm–6:00pm Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies Treating primary central nervous system lymphoma, from methotrexate-based induction and consolidation choices to new drugs aimed at its signaling mutations. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Session Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies How to design clinical trials that alter the gut microbiome in blood cancers, including fecal microbiota transplants to prevent graft-versus-host disease. Talk Dietary and Prebiotic Intervention Strategies Changing gut bacteria through diet and prebiotic fiber, the evidence linking food to patient outcomes, and how to design rigorous nutrition trials. Talk Live Bacterial Therapeutic Intervention Strategies Giving patients defined mixtures of live bacteria to reshape the gut and cut infections after a donor stem cell transplant. Talk Novel Uses of RNA as Therapeutics Synthetic RNAs that exploit faulty splicing to kill cancer cells with splicing-factor mutations, and mRNA vaccines against mis-spliced protein fragments. Session Advancing Personalized Care in Classic Hodgkin Lymphoma Tailoring classic Hodgkin lymphoma treatment to risk, response and circulating tumor DNA to cure with less toxicity, plus personalized follow-up care. Talk Bispecific Antibodies and Cellular Therapies for Diffuse Large B-Cell Lymphoma CAR-T cells and bispecific antibodies for diffuse large B-cell lymphoma, covering efficacy, side effects, patient selection, sequencing, and drugs in development. Talk Immune Determinants of Infections after CAR T- Cell Therapy: A Framework for Prevention and Management Infection risk after CAR-T cell therapy, traced from early immune damage to lasting antibody deficits, and how to prevent infections at each stage. Talk Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Improving Outcomes Beyond the Use of Two Pediatric Regimens Raising cure rates for teens and young adults with acute lymphoblastic leukemia by adding immunotherapy to pediatric-style regimens and limiting lasting harm. Session From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice Case studies showing how real-world multiple myeloma data reveal treatment patterns, outcomes in underrepresented groups, and care gaps, along with their limits. Session The AI Colleague: Promise, Peril, and Practice in Hematology Generative AI in hematology, from chatbot tools usable today to autonomous agents, and safeguards for reliability, bias, and human oversight. |
Instantly find 20 buyers from Memorial Sloan Kettering Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction